Drug – bio-affecting and body treating compositions – Solid synthetic organic polymer as designated organic active... – Aftertreated polymer
Reexamination Certificate
2011-06-28
2011-06-28
Anderson, James D (Department: 1614)
Drug, bio-affecting and body treating compositions
Solid synthetic organic polymer as designated organic active...
Aftertreated polymer
C514S012200, C514S034000, C514S04400A, C514S182000, C514S283000, C514S049000, C514S449000
Reexamination Certificate
active
07968085
ABSTRACT:
A polymeric prodrug composition including a hydrogel, a biologically active moiety and a reversible prodrug linker. The prodrug linker covalently links the hydrogel and the biologically active moiety at a position and the hydrogel has a plurality of pores with openings on its surface. The diameter of the pores is larger than that of the biologically active moiety at least at all points of the pore between at least one of the openings and the position of the biologically active moiety.
REFERENCES:
patent: 2003/0220245 (2003-11-01), Hubbell et al.
patent: 1 053 019 (2003-12-01), None
patent: 1525890 (2005-04-01), None
patent: 1579873 (2005-09-01), None
patent: WO 99/30727 (1999-06-01), None
patent: 9934833 (1999-07-01), None
patent: 0021572 (2000-04-01), None
patent: 0044808 (2000-08-01), None
patent: 0185180 (2001-11-01), None
patent: 02017880 (2002-07-01), None
patent: 02083180 (2002-10-01), None
patent: WO 02/089789 (2002-11-01), None
patent: 03049677 (2003-06-01), None
patent: 03101425 (2003-12-01), None
patent: 2004043493 (2004-05-01), None
Na, Dong Hee, et al.,J. Contr. Rel., vol. 92, 291-299, (2003).
Hennink, W.E. et al.,Adv. Drug Del. Rev., vol. 54, 13-36, (2002).
Hoffman, A.S.,Adv. Drug Del. Rev., vol. 43, 3-12, (2002).
Caliceti, P. et al.,Adv. Drug Del. Rev.,vol. 55, 1261-1277, (2003).
Duncan, R., et al.,J. Contr. Rel.,vol. 74, 135-146, (2001).
Cadee, J.A., et al.,J. Contr. Rel.,vol. 78, 1-13, (2002).
Wiwattanapatapee, W.R., et al.,J. Contr. Rel., vol. 88, 1-9, (2003).
Surini, S., et al.,J. Control. Rel.,vol. 90, 291-301, (2003).
Luo, Y., et al., “A Hyaluronic Acid—Taxol Antitumor Bioconjugate Targeted to Cancer Cells,”Biomacromolecules, vol. 1, 208-218, (2000).
Jeong, B., et al., “Thermogelling Biodegradable Copolymer Aqueous Solutions for Injectable Protein Delivery and Tissue Engineering,”Biomacromolecules, vol. 3, 865-868, (2002).
Sawhney, A.S., et al., “Bioerodible Hydrogels Based on Photopolymerized Poly(ethylene glycol)-co-poly(α-hydroxy acid) Diacrylate Macromer,”Macromolecules, vol. 26, 581-587, (1993).
Cheng, J., et al., “Synthesis of Linear, Beta-Cyclodextrin Based Polymers and Their Camptothecin Conjugates,”Bioconjugate Chem., vol. 14, 1007-1017, (2003).
Satchi-Fainaro, R., et al.,Bioconjugate Chem., vol. 14, 797-804, (2003).
Cavallaro, G., et al.,Bioconjugate Chem., vol. 12, 143-151, (2001).
Lee, S., et al.,Bioconugate. Chem., vol. 12(2), 163-169, (2001).
Greenwald, R.B., et al.,J. Med. Chem., vol. 47, 726-734, (2004).
Bhatt, R., et al., “Synthesis and In Vivo Antitumor Activity of Poly(L-glutamic acid) Conjugates of 20(S)-Campthecin,”J. Med. Chem., vol. 46, 190-193, (2003).
Greenwald, R.B., et al.,J. Med. Chem., vol. 43(3), 457-487, (2000).
Greenwald, R.B., et al.,J. Med. Chem., vol. 42, 3657-3667, (1999).
Garman, A.J., et al.,FEBS Lett., vol. 223(2), 361-365, (1987).
Nektar, Inc., “Nektar Molecule Engineering—Polyethylene Glycol and Derivatives for Advanced PEGylation,” (2003).
Antczak, et al.,Bioorg.&Med. Chem., vol. 9, 2843-2848, (2001).
Peppas, N.A., et al., “Hydrogels in Pharmaceutical Formulations,”Eur. J. Pharm.&Biopharm., vol. 50, 27-46, (2000).
Esfand, R., et al.,Drug Discov. Today, vol. 6(8), 427-436, (2001).
Boas, U., et al.,Chem. Soc. Rev., vol. 33(1), 43-63, (2004).
Grayson, S.M., et al.,Chem. Rev., vol. 101(12), 3819-3868, (2001).
Yasuhiro Matsumura, et al., “A New Concept for Macromolecular Therapeutics in Cancer Chemotherapy: Mechanism of Tumoritropic Accumulation of Proteins and the Antitumor Agent Smancs”, Cancer Research 46, 6387-6392, (Dec. 1986).
Theodora Greene, et al., “Protective Groups in Organic Synthesis” Third Edition (1998).
Bernard Testa, et al., “Hydrolysis in Drug and Prodrug Metabolism/ Chemistry, Biochemistry and Enzymology”, (2002).
Auzanneau, F. et al. , “Synthesis, characterization, and biocompatability of PEGA resins”, “Journal of Peptide Science”, May 1995, pp. 31-44, vol. 1.
Franssen, O. et al. , “Controlled release of a model protein from enzymatically degrading dextran micospheres ”, “Journal of Controlled Release”, May 1999, pp. 219-228, vol. 59, No. 2.
Prestwich, G.D. et al. , “Controlled chemical modification of hyalonuric acid: synthesis, applications, and biodegradation of hydrazide derivative”, Apr. 30, 1998, pp. 93-103, vol. 53, No. 1-3.
Rouquerol J. et al. , “Recommendations for the characterization of porous solids”, “Pure and Applied Chemistry”, 1994, pp. 1739-1758, vol. 66, No. 8.
Hersel Ulrich
Rau Harald
Schnepf Robert
Vetter Dirk
Wegge Thomas
Anderson James D
Ascendis Pharma A/S
Hultquist Steven J.
Hultquist IP
Reynolds Kelly K.
LandOfFree
Hydrogel formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hydrogel formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydrogel formulations will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2723458